Abstract | BACKGROUND: METHODS: Five double-blind, randomized, controlled crossover trials were pooled. All trials had an identical design. Patients were asked to treat three consecutive migraine attacks with frovatriptan 2.5 mg and three consecutive migraine attacks with a comparative triptan ( rizatriptan 10 mg; zomitriptan 2.5 mg; almotriptan 12.5 mg). RESULTS: In this analysis, 117 migraine attacks with aura could be included (intention-to-treat population). The mean headache intensity after 2 hours was 1.2 +/- 1.0 for frovatriptan and 1.6 +/- 1.0 for the other triptans (p<0.05); all triptans showed significant improvement of headache. Frovatriptan resulted in significantly lower relapse rates at 24 hours and 48 hours when taken in migraine attacks with aura. CONCLUSIONS: Our data suggest that frovatriptan is efficacious and even superior in some endpoints also when taken during the headache phase in migraine attacks with aura. This is of particular importance for those many patients who have migraine attacks both without and with aura.
|
Authors | Stefan Evers, Lidia Savi, Stefano Omboni, Carlo Lisotto, Giorgio Zanchin, Lorenzo Pinessi |
Journal | The journal of headache and pain
(J Headache Pain)
Vol. 16
Pg. 514
( 2015)
ISSN: 1129-2377 [Electronic] England |
PMID | 25916333
(Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Carbazoles
- Oxazolidinones
- Triazoles
- Tryptamines
- almotriptan
- zolmitriptan
- rizatriptan
- frovatriptan
|
Topics |
- Adult
- Carbazoles
(administration & dosage, pharmacology)
- Female
- Humans
- Male
- Middle Aged
- Migraine with Aura
(drug therapy)
- Oxazolidinones
(administration & dosage, pharmacology)
- Randomized Controlled Trials as Topic
- Treatment Outcome
- Triazoles
(administration & dosage, pharmacology)
- Tryptamines
(administration & dosage, pharmacology)
|